Relax criteria to increase sign-ups to cancer trials, says ASCOOnly 3% of patients with cancer in the US enrol on a clinical trial – and the American Share XRelax criteria to increase sign-ups to cancer trials, says ASCOhttps://pharmaphorum.com/news/relax-criteria-to-increase-sign-ups-to-cancer-trials-says-asco/
AI system beats radiologists at predicting lung cancer riskA deep learning AI system was able to detect malignant lung nodules better than radiologists in a new Share XAI system beats radiologists at predicting lung cancer riskhttps://pharmaphorum.com/news/ai-system-beats-radiologists-at-predicting-lung-cancer-risk/
Keytruda drives another strong Merck quarter, but what’s next?Merck & Co/MSD’s first quarter followed the predictable pattern of a surge in sales on the back of Share XKeytruda drives another strong Merck quarter, but what’s next?https://pharmaphorum.com/news/keytruda-drives-another-strong-merck-quarter-but-whats-next/
AZ gets NICE nod for ‘big advance’ Imfinzi in lung cancerAstraZeneca has won the backing of NICE for its cancer immunotherapy Imfinzi for non-small cell lung cancer (NSCLC), Share XAZ gets NICE nod for ‘big advance’ Imfinzi in lung cancerhttps://pharmaphorum.com/news/az-gets-nice-nod-for-big-advance-imfinzi-in-lung-cancer/
Roche’s Tecentriq gains new US lung cancer indicationRoche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it Share XRoche’s Tecentriq gains new US lung cancer indicationhttps://pharmaphorum.com/news/roches-tecentriq-gains-new-us-lung-cancer-indication/
Lilly’s Cyramza hits mark in first-line lung cancer trialEli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche’s Tarceva in Share XLilly’s Cyramza hits mark in first-line lung cancer trialhttps://pharmaphorum.com/news/lillys-cyramza-hits-mark-in-first-line-lung-cancer-trial/
Two new cancer Priority Reviews for RocheRoche has announced that the FDA has granted Priority Review to two of its drugs – personalised lung Share XTwo new cancer Priority Reviews for Rochehttps://pharmaphorum.com/news/two-new-cancer-priority-reviews-for-roche/
J&J pays $3.4 billion for robotics firm AurisJohnson & Johnson’s rumoured interest in Auris Health has been confirmed with a $3.3 billion buyout deal that Share XJ&J pays $3.4 billion for robotics firm Aurishttps://pharmaphorum.com/news/jj-pays-robotics-firm-auris/
BMS pulls Opdivo/Yervoy in first-line lung cancerBristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line Share XBMS pulls Opdivo/Yervoy in first-line lung cancerhttps://pharmaphorum.com/news/bms-pulls-opdivo-yervoy-in-first-line-lung-cancer/
